Supplementary Table 2 from A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma

Supplementary Table 2: Analysis of changes in serum VEGF-A and inflammatory cytokines between responders and non-responders after 6 cycles of treatment with bevacizumab and liposomal doxorubicin. *P values are for the difference between responders and non-responders. Abbreviations: IFN, interferon; IL, interleukin; IQR, interquartile range; VEGF, vascular endothelial growth factor